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ABSTRACT 
A new series of 6-subtituted 2-aminobenzothiazole derivatives were designed for their anticonvulsant activity. In order to predict 
their anticonvulsant activities the virtual screening was performed for all the designed compounds using binding affinities to beta-3 
subunit of GABAA receptor. The data obtained from the virtual screening was analyzed by comparing the scores of designed 
compound with the score of the reference molecule. In the present study molegro virtual docker (MVD) version 6.0 were used as 
designing software while the riluzole (2-amino-6-trifluoromethoxybenzothiazole) were taken as reference molecule for the structural 
similarity with designed compound. Compound 14 showed the highest rerank score (-98.98), mol dock score (-118.98) and h-bond (-
3.28) when compared to reference ligand rerank score (-57.74), mol dock score (-76.16) and h-bond (-2.08) for anticonvulsant 
activities of this series. The results obtained provide information about the most active compounds i.e. compound 14 which could be 
a useful information for future design and investigation to construct more active analogs. 
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INTRODUCTION: 
Epilepsy is a most common hyper synchronous brain 
disorders which is characterized by recurrent 
spontaneous seizures of cerebral origin
1
. It is a common 
neurological condition, affecting 0.5-1% or 45-100 
million people of the population worldwide. Some of the 
conventional antiepileptic drugs like benzodiazepine, 
phenytoin, primidone, and phenobarbital, are widely 
used but exhibit unfavorable side effects like headache, 
nausea, vomiting, blurred vision, insomnia, restlessness, 
etc. and thus fails to adequate control of seizures. 
Benzothiazoles and its derivative such as 2-
aminobenzothiazole represent a class of heterocyclic 
scaffold that consists of a five-membered 1,3-thiazole 
ring fused to a benzene ring. Benzothiazoles contain an 
extended π-delocalized system that binds to DNA 
molecules via π–π interactions. Because of this 
interaction, it demonstrates complex biological 
properties such as antimicrobial, anticancer, anti-
inflammatory, antidiabetic, anticonvulsant activities. 
GABAAR’s belong to a superfamily of pentameric 
ligand-gated ion channels (pLGICs) which is also 
known as the Cys-loop receptors, that include the 
cation-selective nicotinic acetylcholine receptors 
(nAChRs) and serotonin type-3 receptors (5HT3Rs), as 
well as anion-selective glycine receptors (GlyRs).  
 
Figure 1: Pharmacophoric features of the titled 
compounds 
 
MATERIALS AND METHODS: 
Molecular docking Study 
The amino acid primary sequence of beta-3 subunit of 
gamma aminobutyric acid (PDB ID:4COF) was 
retrieved from the Protein Data Bank. The docking 
studies were carried out using the Molegro Virtual 
Docker (MVD), a program for predicting the most likely 
conformation of how a ligand will bind to a 
macromolecule. In docking studies the calculated cavity 
was used as active site.  
Structure drawing and energy minimization:  
CS Chem Office 8.0 was used for the sketching of 
molecules. The sketched 2D structures were transformed 
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into 3D structures using module of the program 
(Chem3D Ultra 8.0). The 3D structures were then 
subjected to energy minimization using molecular 
mechanics (MM2) and re optimized via MOPAC until 
the RMS gradient attained a value smaller than 0.0001 
kcal/mol Å. 
Docking Procedure: 
Protein structure of beta-3 subunit of gamma 
aminobutyric acid (PDB ID: 4COF)
2
 was downloaded 
from the Protein Data Bank. Protein model of GABAA. 
Protein ligand docking studies were carried out based on 
the basis of crystal structure of protein Pdb 4COF and 
ligand binding. 
Docking studies shows that Gln224, Gln185, Glu52, 
Tyr143, Val53, Ser51, Leu268, Thr271, Thr225, 
Arg216, Ile264 present in the protein structure of A-
chain of beta-3 subunit of GABAA are highly conserved 
and might play a major role in substrate binding. 
Standard drug riluzole is also found to be bind to these 
amino acids.  
 
Table 1: Substitution on title compound, Mol dock score, rerank score, hydrogen bond energies, of designed 
compounds and reference ligand 
Ligand R1 R2 R3 Mol Dock Score Re rank Score H-Bond 
Comp.1 H H H -107.14 -89.04 -1.09 
Comp.2 H H Cl -106.10 -84.25 -1.11 
Comp.3 H H OH -106.27 -90.71 -0.85 
Comp.4 H OH OCH3 -111.80 -93.71 -085 
Comp.5 H H OCH3 -107.75 -90.11 -2.54 
Comp.6 Cl H H -110.61 -95.64 -4.55 
Comp.7 Cl H Cl -106.61 -88.97 -1.04 
Comp.8 Cl H OH -107.21 -87.13 -0.99 
Comp.9 Cl OH OCH3 -112.40 -92.57 -1.29 
Comp.10 Cl H OCH3 -112.65 -92.07 0 
Comp.11 NO2 H H -114.28 -96.33 -1.22 
Comp.12 NO2 H Cl -116.32 -96.01 -4.95 
Comp.13 NO2 H OH -111.80 -98.98 -3.28 
Comp.14 NO2 OH OCH3 -118.98 -98.98 -3.28 
Comp.15 NO2 H OCH3 -114.70 -84.46 -6.90 
Comp.16 CH3 H H -105.42 -87.45 -0.99 
Comp.17 CH3 H Cl -104.30 -80.76 -2.41 
Comp.18 CH3 H OH -106.08 -85.79 -3.71 
Comp.19 CH3 OH OCH3 -111.12 -89.80 -3.33 
Comp.20 CH3 H OCH3 -111.99 -89.52 -4.82 
Reference    -76.16 -57.74 -2.08 
 
Table 2 Common types of interactions between protein structures of GABAA with most active comp (comp.14) and 
reference comp (riluzole). 
S. No. Interaction Residue 
1. Hydrogen Bond Interaction Tyr143 
2. Steric Interaction Gln224, Thr271, Tyr143 
 
          
Figure 2: 3D-Structure of GABAA Enzyme Binding Pocket of GABAA Enzyme H-Bond Interaction of Reference 
Ligand  
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H-Bond Interaction of Most Active Ligand Steric Interaction of Reference Ligand Steric Interaction of Most Active 
Ligand 
 
RESULTS AND DISCUSSION: 
Evaluation of the docking results was based on protein-
ligand complementarity considering steric and 
electrostatic properties. By analyzing the hydrogen bond 
formed between the fifteen compounds and the active 
site of A- chain of protein we observed almost the 
compounds and riluzole exhibited hydrogen bonds with 
Tyr143. By analyzing the steric interaction formed 
between all the compounds and the active site of A-
chain of protein we observed:(i) compound 1, 2 and 3 
exhibited electrostatic bonds with Gln224, Leu268, 
Thr271, Glu52, Thr225, Gln185, Gln185 (ii) compounds 
4,5 and 6 exhibited electrostatic bonds with Gln224, 
Leu268, Tyr143, Gln185, Arg216, Glu52, Ile264, 
Arg216 (iii) compounds 7,8 and 9 exhibited electrostatic 
bonds with Gln224, Leu268, Gln185, Thr271, Glu52, 
Ile264 (iv) compounds 10,11 and 12 exhibited 
electrostatic bonds with Gln224, Ile264, Glu52, Thr271, 
Gln185, Arg216, Tyr143. Compound 14 experiences a 
lower intermolecular energy in terms of Mol docks score 
and rerank score or more stable complex because the 
distance between the two aromatic rings is larger. The 
neat results of the above interactions are given in terms 
of mol dock score, rerank score and hydrogen binding 
energies toward the active site of A-chain of beta-3 
subunit of GABAA as depicted in Table 1. According to 
these values, compound 14 presented an estimated 
affinity to the 4COF active site higher than the standard 
compound riluzole the most promising reference 
compound. 
CONCLUSIONS: 
The scoring results reveal the higher negative mol dock 
score and rerank score of the test compounds (especially 
compound 14) in comparison to riluzole. It was also 
observed that the commercial drug riluzole and all the 20 
designed compounds binds to the specific binding sites 
and shows only one hydrogen bond interaction i.e. 
Tyr143. Here docking study provides an important 
insight in designing the structures of the most potent 
compound and subsequent construction of library of 
such derivatives. 
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